LLY

The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.

Evan Seigerman, BMO Capital Markets senior pharma analyst, joins 'Squawk Box' to discuss the state of the pharma sector, latest GLP-1 developments, weight-loss drug market competition, and more.

The highest dose of a single injection reduced cholesterol levels by 62% in patients, according to Eli Lilly's recently published study.

Surging demand for the memory chipmaker's AI products has sent its stock soaring. But a rally this steep doesn't come without risk.

Eli Lilly's fair value estimate has shifted slightly from US$1,209.21 to US$1,211.03 per share, a small move that still reflects meaningful debate around what is already priced into the stock. Much of the recent analyst discussion links this updated target range to retatrutide Phase 3 data, with bulls highlighting GLP-1 leadership and bears questioning how much future obesity growth is already embedded. As you read on, you will see how these competing views shape the evolving narrative around...

The S&P 500 is on pace to close at fresh record highs today on positive breadth.

Investors remained hopeful about U.S.-Iran talks, offsetting recent military exchanges.

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% an